MedTrace Logo

Study of Eltrombopag in Platelet Refractory Thrombocytopenia

NCT01194167 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-11-25

No results posted yet for this study

Summary

This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia (low platelet count). Eltrombopag is approved by the FDA for the treatment of thrombocytopenia (low platelet count) in adults who have had an insufficient response to medications such as corticosteroids and immunoglobulins. Eltrombopag is not approved by the FDA (Food and Drug Administration) for the treatment of thrombocytopenia refractory to platelet transfusion and so for this study is considered investigational.

Conditions

Interventions

DRUG

Eltrombopag

75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Patricia Carey, MD · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01194167 on ClinicalTrials.gov